Literature DB >> 24352201

[Atypical femoral fractures in bisphosphonate therapy].

A Ballaschk1, N Kalaitzis, M Röpke, S Piatek.   

Abstract

Bisphosphonates (BP) play an important role in the therapy of osteoporosis as they effectively reduce the risk of fractures. Atypical femoral fractures (AFF) have recently been described as an adverse effect of BP treatment. We present 3 women under therapy with BP, who had five AFF, among these three complete and two incomplete fractures. The incidence of AFF under therapy with BP is low, and the benefit regarding reduction of spinal fractures and fractures of the proximal femur is much higher than the risk for an AFF.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 24352201     DOI: 10.1007/s00113-013-2526-7

Source DB:  PubMed          Journal:  Unfallchirurg        ISSN: 0177-5537            Impact factor:   1.000


  9 in total

1.  Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures.

Authors:  Eve Donnelly; Dennis S Meredith; Joseph T Nguyen; Brian P Gladnick; Brian J Rebolledo; Andre D Shaffer; Dean G Lorich; Joseph M Lane; Adele L Boskey
Journal:  J Bone Miner Res       Date:  2012-03       Impact factor: 6.741

2.  Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group.

Authors:  D M Black; D E Thompson; D C Bauer; K Ensrud; T Musliner; M C Hochberg; M C Nevitt; S Suryawanshi; S R Cummings
Journal:  J Clin Endocrinol Metab       Date:  2000-11       Impact factor: 5.958

3.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women.

Authors:  Laura Y Park-Wyllie; Muhammad M Mamdani; David N Juurlink; Gillian A Hawker; Nadia Gunraj; Peter C Austin; Daniel B Whelan; Peter J Weiler; Andreas Laupacis
Journal:  JAMA       Date:  2011-02-23       Impact factor: 56.272

Review 5.  Atypical subtrochanteric and femoral shaft fractures and possible association with bisphosphonates.

Authors:  Jeri W Nieves; Felicia Cosman
Journal:  Curr Osteoporos Rep       Date:  2010-03       Impact factor: 5.096

Review 6.  Bisphosphonate therapy and atypical fractures.

Authors:  Anas Saleh; Vishal V Hegde; Anish G Potty; Joseph M Lane
Journal:  Orthop Clin North Am       Date:  2013-02-21       Impact factor: 2.472

7.  Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Peter R Ebeling; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David Dempster; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Kenneth Koval; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Howe Tet Sen; Marjolein C H van der Meulen; Robert S Weinstein; Michael Whyte
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

8.  Incidence of atypical nontraumatic diaphyseal fractures of the femur.

Authors:  Richard M Dell; Annette L Adams; Denise F Greene; Tadashi T Funahashi; Stuart L Silverman; Eric O Eisemon; Hui Zhou; Raoul J Burchette; Susan M Ott
Journal:  J Bone Miner Res       Date:  2012-12       Impact factor: 6.741

9.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.